Total Payments
$5,383
2024 Payments
$125.00
Companies
38
Transactions
172
Medicare Patients
2,469
Medicare Billing
$386,591
Payment Breakdown by Category
Food & Beverage$4,463 (82.9%)
Education$920.45 (17.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,463 | 150 | 82.9% |
| Education | $920.45 | 22 | 17.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $743.63 | 14 | $0 (2022) |
| Amgen Inc. | $661.84 | 18 | $0 (2018) |
| Novartis Pharmaceuticals Corporation | $371.22 | 10 | $0 (2018) |
| Lilly USA, LLC | $312.65 | 7 | $0 (2018) |
| Astellas Pharma US Inc | $291.23 | 7 | $0 (2018) |
| Celgene Corporation | $267.84 | 11 | $0 (2018) |
| Janssen Biotech, Inc. | $247.32 | 6 | $0 (2019) |
| Genentech USA, Inc. | $211.87 | 14 | $0 (2018) |
| Shire North American Group Inc | $192.96 | 5 | $0 (2018) |
| AstraZeneca Pharmaceuticals LP | $181.98 | 4 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $125.00 | 1 | PFIZER INC. ($125.00) |
| 2022 | $410.26 | 4 | E.R. Squibb & Sons, L.L.C. ($287.90) |
| 2021 | $13.93 | 1 | Acrotech Biopharma LLC ($13.93) |
| 2019 | $199.63 | 5 | Janssen Biotech, Inc. ($186.84) |
| 2018 | $2,693 | 88 | Amgen Inc. ($551.81) |
| 2017 | $1,941 | 73 | E.R. Squibb & Sons, L.L.C. ($322.58) |
All Payment Transactions
172 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/11/2024 | PFIZER INC. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Oncology | ||||||
| 09/20/2022 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $37.90 | General |
| Category: Oncology | ||||||
| 06/21/2022 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $125.00 | General |
| Category: Oncology | ||||||
| 05/17/2022 | E.R. Squibb & Sons, L.L.C. | ONUREG (Drug) | Food and Beverage | Cash or cash equivalent | $125.00 | General |
| Category: Oncology | ||||||
| 03/03/2022 | Takeda Pharmaceuticals U.S.A., Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $122.36 | General |
| Category: ONCOLOGY | ||||||
| 04/01/2021 | Acrotech Biopharma LLC | BELEODAQ (Drug) | Education | In-kind items and services | $13.93 | General |
| Category: ONCOLOGY | ||||||
| 12/04/2019 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Education | In-kind items and services | $59.99 | General |
| Category: Oncology | ||||||
| 11/15/2019 | Janssen Biotech, Inc. | Erleada (Drug) | Food and Beverage | In-kind items and services | $75.00 | General |
| Category: Oncology | ||||||
| 11/07/2019 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $42.97 | General |
| Category: Oncology | ||||||
| 03/05/2019 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $8.88 | General |
| Category: Oncology | ||||||
| 01/03/2019 | Puma Biotechnology, Inc. | Nerlynx (Drug) | Food and Beverage | In-kind items and services | $12.79 | General |
| Category: Oncology | ||||||
| 12/19/2018 | Lilly USA, LLC | VERZENIO (Drug) | Food and Beverage | In-kind items and services | $8.43 | General |
| Category: Oncology | ||||||
| 12/07/2018 | E.R. Squibb & Sons, L.L.C. | EMPLICITI (Biological) | Food and Beverage | Cash or cash equivalent | $18.62 | General |
| Category: Oncology | ||||||
| 12/06/2018 | Amgen Inc. | Enbrel (Biological), Prolia | Food and Beverage | In-kind items and services | $7.65 | General |
| Category: Inflammation | ||||||
| 11/28/2018 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $17.53 | General |
| Category: Oncology | ||||||
| 11/26/2018 | Lilly USA, LLC | CYRAMZA (Drug) | Food and Beverage | In-kind items and services | $18.30 | General |
| Category: Oncology | ||||||
| 11/20/2018 | Lilly USA, LLC | — | Food and Beverage | In-kind items and services | $94.09 | General |
| 11/20/2018 | GENZYME CORPORATION | LIBTAYO (Drug) | Food and Beverage | In-kind items and services | $18.94 | General |
| Category: ONCOLOGY | ||||||
| 11/16/2018 | Celgene Corporation | Revlimid (Drug) | Food and Beverage | In-kind items and services | $20.92 | General |
| Category: Hematology / Oncology | ||||||
| 11/15/2018 | Amgen Inc. | Neulasta (Biological), Vectibix | Food and Beverage | In-kind items and services | $7.77 | General |
| Category: Oncology | ||||||
| 11/12/2018 | Seattle Genetics, Inc. | ADCETRIS (Biological) | Food and Beverage | In-kind items and services | $14.48 | General |
| Category: Oncology | ||||||
| 11/06/2018 | SANOFI-AVENTIS U.S. LLC | JEVTANA (Drug) | Food and Beverage | In-kind items and services | $10.96 | General |
| Category: ONCOLOGY | ||||||
| 10/30/2018 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $31.46 | General |
| Category: Oncology | ||||||
| 10/29/2018 | Astellas Pharma US Inc | XTANDI (Drug) | Education | In-kind items and services | $15.52 | General |
| Category: ONCOLOGY | ||||||
| 10/27/2018 | Teva Pharmaceuticals USA, Inc. | — | Food and Beverage | In-kind items and services | $53.84 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 140 | 148 | $27,337 | $5,221 |
| 2022 | 4 | 718 | 1,630 | $291,130 | $125,161 |
| 2021 | 5 | 801 | 1,666 | $299,902 | $136,125 |
| 2020 | 4 | 810 | 1,765 | $325,869 | $120,084 |
Total Patients
2,469
Total Services
5,209
Medicare Billing
$386,591
Procedure Codes
16
All Medicare Procedures & Services
16 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 117 | 125 | $20,563 | $3,408 | 16.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 12 | 12 | $4,233 | $1,133 | 26.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 11 | 11 | $2,541 | $680.58 | 26.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 495 | 1,308 | $215,166 | $91,872 | 42.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 144 | 219 | $50,589 | $23,252 | 46.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 46 | 46 | $16,227 | $6,486 | 40.0% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 33 | 57 | $9,149 | $3,551 | 38.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 470 | 1,195 | $194,486 | $88,664 | 45.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 179 | 277 | $63,364 | $30,187 | 47.6% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 69 | 69 | $24,098 | $9,331 | 38.7% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 50 | 87 | $13,964 | $5,980 | 42.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 33 | 38 | $3,990 | $1,963 | 49.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 466 | 1,274 | $207,344 | $75,734 | 36.5% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 209 | 328 | $75,030 | $27,861 | 37.1% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 97 | 97 | $33,877 | $12,225 | 36.1% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 38 | 66 | $9,618 | $4,264 | 44.3% |
About Dr. Kevin Weeks, DO
Dr. Kevin Weeks, DO is a Hematology healthcare provider based in Sequim, Washington. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/07/2006. The National Provider Identifier (NPI) number assigned to this provider is 1811090236.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Kevin Weeks, DO has received a total of $5,383 in payments from pharmaceutical and medical device companies, with $125.00 received in 2024. These payments were reported across 172 transactions from 38 companies. The most common payment nature is "Food and Beverage" ($4,463).
As a Medicare-enrolled provider, Weeks has provided services to 2,469 Medicare beneficiaries, totaling 5,209 services with total Medicare billing of $386,591. Data is available for 4 years (2020–2023), covering 16 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology
- Other Specialties Medical Oncology
- Location Sequim, WA
- Active Since 09/07/2006
- Last Updated 10/31/2018
- Taxonomy Code 207RH0000X
- Entity Type Individual
- NPI Number 1811090236
Products in Payments
- OPDIVO (Biological) $509.83
- Revlimid (Drug) $202.50
- Kyprolis (Biological) $181.07
- ELAPRASE (Biological) $179.93
- GILOTRIF (Drug) $162.86
- PROVENGE (Drug) $131.59
- IMBRUVICA (Drug) $129.35
- MEKINIST (Drug) $126.54
- ADCETRIS (Biological) $126.50
- TAGRISSO (Drug) $125.65
- ONUREG (Drug) $125.00
- PADCEV (Biological) $125.00
- NINLARO (Drug) $122.36
- KEYTRUDA (Biological) $121.53
- Neulasta (Biological) $98.89
- SOLIRIS (Drug) $87.37
- Aimovig (Biological) $85.70
- Aliqopa (Drug) $85.07
- Cabometyx (Drug) $81.89
- Perjeta (Biological) $80.00
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.